CICMD Associate Director Michelle Cardel Featured in Vox Article: Obesity in the age of Ozempic

“For the first time in many of these patients’ lives, they have a more neutral feeling toward food,” Michelle Cardel, associate director for the Center for Integrative Cardiovascular and Metabolic Diseases at the University of Florida who heads research at Weight Watchers, observed. GLP-1-based drugs “reduce the chatter in their brain; they quiet obsessive food thoughts.”

https://www.vox.com/science-and-health/23584679/ozempic-wegovy-semaglutide-weight-loss-obesity